Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

Mogensen AW et al. The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer ...